Accelero Ph2 randomized open label study of neoadjuvant zanidatamab + chemo in HER2+ breast
Phase II Clinical Trial
JZP598-208: A Phase 2 randomized multicenter open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer.